^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Qibeian (iparomlimab/tuvonralimab)

    i
    Other names: PSB205 , PSB-205, PSB 205 , Anti-PD-1/CTLA-4 MabPair, QL1706, PBS-103/PBS-105, QL 1706, QL-1706
    Company:
    Qilu Pharma, Sound Biologics
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    1d
    TTE Study of QL1706 in Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov)
    P=N/A, N=280, Not yet recruiting, Qilu Hospital of Shandong University
    New trial • Real-world evidence
    |
    Qibeian (iparomlimab/tuvonralimab)
    2d
    QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Fujian Medical University
    New P2 trial
    |
    Avastin (bevacizumab) • Qibeian (iparomlimab/tuvonralimab)
    6d
    QUARTZ-CC: Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P2, N=103, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    cisplatin • carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    7d
    A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy (clinicaltrials.gov)
    P2, N=28, Recruiting, Shanghai Chest Hospital | Active, not recruiting --> Recruiting | Initiation date: Jul 2025 --> Oct 2025
    Enrollment open • Trial initiation date • IO biomarker
    |
    cisplatin • carboplatin • Qibeian (iparomlimab/tuvonralimab)
    10d
    QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P2/3, N=120, Not yet recruiting, Sun Yat-sen University
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Focus V (anlotinib) • Qibeian (iparomlimab/tuvonralimab)
    15d
    A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. (clinicaltrials.gov)
    P=N/A, N=59, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New trial
    |
    cyclophosphamide • epirubicin • Qibeian (iparomlimab/tuvonralimab)
    17d
    QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    20d
    A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P3, N=486, Not yet recruiting, Fujian Cancer Hospital
    New P3 trial
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    27d
    QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=34, Recruiting, Jiangsu Cancer Institute & Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Focus V (anlotinib) • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    1m
    Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair Deficiency (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2 trial • Mismatch repair • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Qibeian (iparomlimab/tuvonralimab)
    1m
    INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma (clinicaltrials.gov)
    P3, N=226, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting | Initiation date: Jun 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    1m
    NEO-ITHRAN: Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer (clinicaltrials.gov)
    P2, N=55, Recruiting, RenJi Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)